Last reviewed · How we verify
LTZ-301
At a glance
| Generic name | LTZ-301 |
|---|---|
| Sponsor | LTZ Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LTZ-301 CI brief — competitive landscape report
- LTZ-301 updates RSS · CI watch RSS
- LTZ Therapeutics, Inc. portfolio CI